For the second time in the past few months, a Democratic lawmaker is after Pfizer (PFE) to explain its pricing decisions, especially now that the drug maker is lifting a brief, self-imposed ban on price hikes with plans to boost the cost of more than 40 medicines next month.

In a letter to Pfizer chief executive Ian Read, Sen. Tammy Baldwin (D-Wis.) chastised him for “playing political games” by proceeding with the price hikes and for failing to answers questions that she posed last July, when Read tried to appease President Trump by rolling back a slew of increases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy